NovaBridge Biosciences
Close on Oct 19, 2026
About NovaBridge Biosciences
Pharmaceutical Preparations, SIC 2834
NovaBridge Biosciences is a clinical-stage biopharmaceutical enterprise focused on discovering, developing, and commercializing novel or differentiated biologic therapeutics. The company primarily directs its research efforts toward treatments in the fields of oncology and ophthalmology. It advances a proprietary pipeline of investigational drug candidates alongside partnered development programs with international pharmaceutical organizations. Its customer and collaborator base comprises global biopharmaceutical licensees, commercial healthcare providers, and targeted patient populations requiring advanced biologic interventions.
Incorporated as an exempted company in the Cayman Islands, the organization maintains its principal executive offices in Rockville, Maryland, United States. Its continuing business operations and clinical pipeline activities are managed through operating subsidiaries located in the United States and China following the divestiture of its former Greater China business unit.
Summary of the business section of NovaBridge Biosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- NovaBridge Biosciences
- Headquarters
- Rockville, MD
- Address
- Suite 400, 2440 Research Blvd 20850
- Phone
- (301) 670-2800
- Website
- imabbiopharma.com
- Employees
- 220, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- E9
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers Zhong Tian LLP, Shanghai, the Peoples Republic of China
Stock & identifiers
- Ticker
- NBP
- Exchange
- Nasdaq
- IPO date
- Jan 21, 2020
- Shares outstanding
- 265M, Dec 31, 2025
- Filer category
- Non-accelerated filer
- SEC CIK
- 1778016
- CUSIP
- 44975P103
- ISIN
- US44975P1030
- LEI
- 549300L1A5T19703RR64
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Srishti Gupta | Chief Executive Officer, Director | – |
| Xi-Yong Fu | See Remarks, Director | 59,823 |
| Phillip Andrew Dennis | Chief Medical Officer | 173,427 |
| Sean Wuxiong Cao | Chief Bus. Development Officer | 266,467 |
| Cong Claire Xu | EVP, Clinical Development | 304,201 |
| Mark Arnold Hagler | Chief Commercial Officer | 230,000 |
| Liwei Lorraine Lin | General Counsel | – |
| Denny Hsueh Wen Chu | See Remarks | – |
| Xiaofan Neo Zhang | Chief Investment Officer | 874,000 |
| Adeline Yi Zhang | Global Controller | – |
| Joanna Xuqiong Wu | See Remarks | 5,750 |
| Ming Kyler Lei | Chief Financial Officer | – |
| Martin William Dewhurst | Director | – |
| Robert A. Lenz | Director | 17,218 |
| Wei Fu | Director | 30,499,699 |
| Conor Chia-hung Yang | Director | – |
| Xin Liu | Director | – |
| Chun Kwok Alan Au | Director | – |
| Ian Ying Woo | Director | – |
| Emmett Cunningham | Director | – |
Employees
Headcount reported in annual reports
“We had 30, 32, and 220 employees as of December 31, 2025, 2024 and 2023, respectively.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 28, 2025 | Name change | Name changed from I-Mab to NovaBridge Biosciences |
| Jan 21, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 3, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |